ROCKVILLE, MD — October 22, 2025 — Leads & Copy —Shuttle Pharmaceuticals Holdings (NASDAQ:SHPH) has signed a definitive Letter of Intent (LOI) to acquire Molecule.ai, an artificial intelligence platform designed to help machines reason like scientists.
The agreement stipulates that Shuttle, or one of its affiliates, will acquire substantially all of Molecule’s assets and liabilities for approximately $10 million, payable in a mix of cash and common stock. The structure provides Shuttle with full flexibility to determine the ratio and timing of payments, which will be tied to specific performance milestones.
Through Molecule.ai’s platform, the company can train models that don’t just recall past data; they reason with it. The system can predict molecular interactions, recognize patterns invisible to the human eye, and iterate designs in real-time. Each run through the loop makes the next one sharper.
The integration of Molecule.ai’s autonomous systems will give it something the biotech world has never really had before: a way to make learning perpetual.
EMAIL Contact: info@hawkpointmedia.com
Source: Shuttle Pharmaceuticals Holdings
